Shots:
- NCCN and Pfizer have issued an open RFP that develop and validate enduring approaches to improve the safe, effective, and efficient adoption of biosimilars in oncology
- The RFP supports approaches to improve the processes related to biosimilar adoption in oncology. Letters of Intent are welcome from academic or community centers, patient advocacy groups and HCPs organizations in the US and are due on Sept 09, 2020
- The NCCN ORP will boost up the discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology
Click here to read full press release/ article | Ref: PRNewswire | Image: NCCN
